CN101360999B - 眼内压调节早期基因及其用途 - Google Patents

眼内压调节早期基因及其用途 Download PDF

Info

Publication number
CN101360999B
CN101360999B CN2006800515976A CN200680051597A CN101360999B CN 101360999 B CN101360999 B CN 101360999B CN 2006800515976 A CN2006800515976 A CN 2006800515976A CN 200680051597 A CN200680051597 A CN 200680051597A CN 101360999 B CN101360999 B CN 101360999B
Authority
CN
China
Prior art keywords
expression
ipreg
macroglobulin
rgc
gene
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
CN2006800515976A
Other languages
English (en)
Chinese (zh)
Other versions
CN101360999A (zh
Inventor
H·U·萨拉戈维
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
McGill University
Original Assignee
McGill University
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by McGill University filed Critical McGill University
Publication of CN101360999A publication Critical patent/CN101360999A/zh
Application granted granted Critical
Publication of CN101360999B publication Critical patent/CN101360999B/zh
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/5308—Immunoassay; Biospecific binding assay; Materials therefor for analytes not provided for elsewhere, e.g. nucleic acids, uric acid, worms, mites
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/16—Ophthalmology
    • G01N2800/168—Glaucoma

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Biomedical Technology (AREA)
  • Cell Biology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Analytical Chemistry (AREA)
  • Biotechnology (AREA)
  • Physics & Mathematics (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Microbiology (AREA)
  • Food Science & Technology (AREA)
  • Toxicology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
CN2006800515976A 2005-11-22 2006-11-22 眼内压调节早期基因及其用途 Expired - Fee Related CN101360999B (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US73957005P 2005-11-22 2005-11-22
US60/739,570 2005-11-22
PCT/US2006/045169 WO2007062101A2 (en) 2005-11-22 2006-11-22 Intraocular pressure-regulated early genes and uses thereof

Publications (2)

Publication Number Publication Date
CN101360999A CN101360999A (zh) 2009-02-04
CN101360999B true CN101360999B (zh) 2013-07-17

Family

ID=38067890

Family Applications (1)

Application Number Title Priority Date Filing Date
CN2006800515976A Expired - Fee Related CN101360999B (zh) 2005-11-22 2006-11-22 眼内压调节早期基因及其用途

Country Status (7)

Country Link
US (1) US8563520B2 (cg-RX-API-DMAC7.html)
EP (1) EP1957986B1 (cg-RX-API-DMAC7.html)
JP (1) JP5249774B2 (cg-RX-API-DMAC7.html)
CN (1) CN101360999B (cg-RX-API-DMAC7.html)
AU (1) AU2006318550A1 (cg-RX-API-DMAC7.html)
CA (1) CA2630668C (cg-RX-API-DMAC7.html)
WO (1) WO2007062101A2 (cg-RX-API-DMAC7.html)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH0634001Y2 (ja) 1989-02-02 1994-09-07 石川島播磨重工業株式会社 水平対向型幅プレスの金型取付装置
AU2006318550A1 (en) * 2005-11-22 2007-05-31 Mcgill University Intraocular pressure-regulated early genes and uses thereof
US8648169B2 (en) 2006-12-05 2014-02-11 The Royal Institution For The Advancement Of Learning/Mcgill University Methods of use of Trk receptor modulators
WO2010118340A1 (en) * 2009-04-09 2010-10-14 University Of Medicine And Dentistry Of New Jersey Treatment of cutaneous hemangioma
CN102210851A (zh) * 2011-05-31 2011-10-12 中国人民解放军第三军医大学第一附属医院 人αB-晶体蛋白在制备保护视网膜神经节细胞的药物中的应用
US20140228299A1 (en) * 2011-09-20 2014-08-14 National University Corporation Tokyo Medical And Dental University Prophylactic and therapeutic agent for neurological diseases using lipoproteins and prophylactic and therapeutic method for neurological diseases
EP3140422A1 (en) * 2014-05-03 2017-03-15 The Regents of The University of California Methods of identifying biomarkers associated with or causative of the progression of disease, in particular for use in prognosticating primary open angle glaucoma
US20180021404A1 (en) * 2015-02-20 2018-01-25 The Regents Of The University Of California Methods and compositions for treating glaucoma
JP7033840B2 (ja) * 2016-06-17 2022-03-11 ユーロイミューン・メディツィニシェ・ラボルディアグノシュティカ・アクチエンゲゼルシャフト 神経自己免疫疾患の診断
CN106434933A (zh) * 2016-10-11 2017-02-22 青岛大学 Crybb2基因在制备检测先天性白内障制品中的应用
US12606868B2 (en) 2020-02-24 2026-04-21 The Board Of Regents Of The University Of Texas System Molecular biomarkers and targets for Fuchs' endothelial corneal dystrophy and glaucoma

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN2237430Y (zh) * 1995-07-20 1996-10-16 北京市橡胶制品设计研究院 青光眼房水引流盘
WO2004069258A2 (de) * 2003-02-07 2004-08-19 Florian Lang Verwendung der sgk-genfamilie zur diagnose und zur therapie von katarakt und glaukom
WO2005060542A2 (en) * 2003-12-17 2005-07-07 Alcon, Inc. Use of serum amyloid a gene in diagnosis and treatment of glaucoma and identification of anti-glaucoma agents

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4911920A (en) * 1986-07-30 1990-03-27 Alcon Laboratories, Inc. Sustained release, comfort formulation for glaucoma therapy
US6441047B2 (en) * 1995-11-17 2002-08-27 Alcon Manufacturing Ltd.. Combination therapy for treating glaucoma
US6482854B1 (en) * 1999-03-25 2002-11-19 Massachusetts Eye And Ear Infirmary Glaucoma treatment
DE602005012812D1 (de) * 2005-06-13 2009-04-02 Primm Srl Heterodimere Peptide mit NGF Aktivität und deren Verwendung zur Behandlung von neurodegenerativen Krankheiten
AU2006318550A1 (en) * 2005-11-22 2007-05-31 Mcgill University Intraocular pressure-regulated early genes and uses thereof
EP1921087A1 (en) 2006-11-10 2008-05-14 Primm S.R.L. Process for the preparation of cyclic peptides

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN2237430Y (zh) * 1995-07-20 1996-10-16 北京市橡胶制品设计研究院 青光眼房水引流盘
WO2004069258A2 (de) * 2003-02-07 2004-08-19 Florian Lang Verwendung der sgk-genfamilie zur diagnose und zur therapie von katarakt und glaukom
WO2005060542A2 (en) * 2003-12-17 2005-07-07 Alcon, Inc. Use of serum amyloid a gene in diagnosis and treatment of glaucoma and identification of anti-glaucoma agents

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
Marcelo Rudzinski et al..Changes in Retinal Expression of Neurotrophins and Neurotrophin Receptors Induced by Ocular Hypertension.《Journal of Neurobioligy》.2004,第58卷(第3期),第350页左栏最后一段. *

Also Published As

Publication number Publication date
CA2630668A1 (en) 2007-05-31
JP5249774B2 (ja) 2013-07-31
US8563520B2 (en) 2013-10-22
WO2007062101A2 (en) 2007-05-31
EP1957986B1 (en) 2017-05-24
EP1957986A2 (en) 2008-08-20
WO2007062101A3 (en) 2008-03-06
AU2006318550A1 (en) 2007-05-31
CA2630668C (en) 2016-07-12
CN101360999A (zh) 2009-02-04
US20080305103A1 (en) 2008-12-11
JP2009519232A (ja) 2009-05-14

Similar Documents

Publication Publication Date Title
US8563520B2 (en) Treatment of ocular disease with inhibitors of alpha2 macroglobulin protein
Besirli et al. Autophagy activation in the injured photoreceptor inhibits fas-mediated apoptosis
Chinskey et al. Control of photoreceptor autophagy after retinal detachment: the switch from survival to death
Xie et al. Intranasal administration of recombinant Netrin-1 attenuates neuronal apoptosis by activating DCC/APPL-1/AKT signaling pathway after subarachnoid hemorrhage in rats
Kapell et al. Neuron-oligodendrocyte potassium shuttling at nodes of Ranvier protects against inflammatory demyelination
US20200206167A1 (en) Inhibitor of trpm-4 ion channel for treating or preventing neurodegeneration
Li et al. The P300/XBP1s/Herpud1 axis promotes macrophage M2 polarization and the development of choroidal neovascularization
US20210113687A1 (en) Methods for treating inflammation
US20080260644A1 (en) Chloride transport upregulation for the treatment of traumatic brain injury
US20080242608A1 (en) Methods and compositions for treating and preventing neurologic disorders
JP2016523969A (ja) エンドセリンb受容体アゴニストを用いた、神経精神疾患を治療するための組成物及び方法
WO2014165181A1 (en) Compositions for treatment of retinal detachment
Bessero et al. Role of the c‐Jun N‐terminal kinase pathway in retinal excitotoxicity, and neuroprotection by its inhibition
US20070173453A1 (en) Methods of preventing or treating brain ischemia or brain injury
Liu et al. Opticin Ameliorates Hypoxia-Induced Retinal Angiogenesis by Suppression of Integrin α2-I Domain–Collagen Complex Formation and RhoA/ROCK1 Signaling
US20170266146A1 (en) Compositions and methods for treatment of retinal degenerative diseases
Cooper et al. The relationship between neurotrophic factors and CaMKII in the death and survival of retinal ganglion cells
AU2012202220A1 (en) Intraocular pressure-regulated early genes and uses thereof
US10369191B2 (en) Modulation of epigenetic stress response
US20120232121A1 (en) Use of sarcoplasmic ca2+-atpase type 2 protein for diagnosing and treating learning or mental disorders
US20070087966A1 (en) Prolactin and chronic and acute pain disorders
EP3003341B1 (en) Compositions for use in methods for treatment of retinal degenerative diseases
Tapanes Glial Derived D-serine Mediates Synaptic Damage in the Traumatically Injured Brain
Klein et al. Why Alzheimer’s is a disease of memory: Synaptic targeting by pathogenic Aβ oligomers (ADDLs)
US20090048146A1 (en) Use of agents that upregulate crystallin expression in the retina and optic nerve head

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C14 Grant of patent or utility model
GR01 Patent grant
CF01 Termination of patent right due to non-payment of annual fee
CF01 Termination of patent right due to non-payment of annual fee

Granted publication date: 20130717